In contemporary pharmacology and neurobiology, the term agonist–antagonist denotes a complex class of ligands that display diametrically opposed functional activities depending on receptor subtype, baseline neurochemical tone, or tissue-specific signaling pathways. These bifunctional molecules defy simple binary classifications of pharmacological activation and blockade, providing therapeutic versatility across disciplines such as addiction medicine, anesthesiology, and pain management. By engaging receptor conformations with differential efficacy, agonist–antagonists achieve nuanced physiological modulations that classic full agonists or competitive antagonists cannot replicate.
Agonist–Antagonist
1. Concise Definition
An agonist–antagonist (often termed a mixed agonist–antagonist) is a pharmacological agent that binds to multiple receptor subtypes within a biological system, exerting full or partial agonist actions at one or more specific subtypes while functioning as an antagonist at others. Alternatively, the designation describes a single-target partial agonist that elicits agonistic downstream signaling in the absence of endogenous ligand but acts as a functional antagonist in the presence of high-efficacy full agonists by competitively displacing them.
Within receptor pharmacology, this hybrid behavioral profile permits an agent to stimulate desired intracellular signaling cascades while concurrently insulating the biological system from undesirable physiological consequences mediated by alternate receptor subtypes. In neuropsychopharmacology, the concept is most famously illustrated by mixed opioid ligands that activate kappa-opioid receptors to produce analgesia while simultaneously blocking mu-opioid receptors to avert euphoric reinforcement and severe respiratory depression.
Beyond the opioid system, the agonist–antagonist paradigm extends to monoaminergic, purinergic, and endocrine receptor networks. In these varied physiological niches, the construct highlights the continuum of ligand intrinsic efficacy, demonstrating that biological output is not merely a reflection of receptor occupancy, but rather the result of precise, ligand-induced conformational changes within macromolecular receptor complexes.
2. Etymology & Linguistic Origin
The compound designation agonist–antagonist combines two ancient Greek roots bridged by an en-dash to capture functional duality. The term agonist derives from the Greek agōnistēs (ἀγωνιστής), historically meaning an “actor,” “competitor,” or “champion in the games,” which in turn originates from agōn (ἀγών), signifying a “contest,” “struggle,” or “gathering.” In twentieth-century biological nomenclature, an agonist became designated as a molecular “prime mover” or active instigator of physiological response.
Conversely, antagonist originates from antagōnistēs (ἀνταγωνιστής), compounding anti- (ἀντί, meaning “against” or “opposite”) with agōnistēs, literally translating to an “adversary,” “opponent,” or “rival.” When modern pharmacology matured during the mid-twentieth century through the pioneering work of figures such as A. J. Clark, R. P. Stephenson, and E. J. Ariëns, researchers observed molecules that could simultaneously compete for binding sites while producing paradoxical functional outputs. The hyphenated or en-dashed compound agonist–antagonist entered formal medical discourse in the 1960s and 1970s to classify synthetic opioids, such as pentazocine and nalbuphine, that failed to conform to strict unidirectional actions at opioid receptors.
3. Pronunciation & Grammatical Form
Pronunciation: Phonetically transcribed in the International Phonetic Alphabet (IPA) as /æɡ.ə.nɪst ænˈtæɡ.ə.nɪst/ (American English) or /ˈæɡ.ə.nɪst ænˈtæɡ.ən.ɪst/ (British English).
Grammatical Form: The term functions as both a compound noun and a compound attributive adjective. As a countable noun (plural: agonist–antagonists or mixed agonist–antagonists), it identifies the chemical compound itself (e.g., “Buprenorphine is a clinically indispensable agonist–antagonist”). As an adjective, it modifies pharmacological terms such as agent, ligand, profile, or properties (e.g., “The drug exhibits distinct agonist–antagonist behavior across different tissue preparations”). Variants in scientific literature include mixed agonist-antagonist, partial agonist/antagonist, and bifunctional receptor ligand.
4. Detailed Conceptual Explanation
To conceptualize the agonist–antagonist phenomenon, one must distinguish between two fundamental pharmacological parameters: affinity and intrinsic efficacy. Affinity quantifies the chemical avidity with which a ligand occupies a receptor binding pocket, whereas intrinsic efficacy describes the ligand’s capacity to induce a conformational transition in the receptor that activates coupled heterotrimeric G proteins or recruits arrestin scaffolds. An agonist–antagonist leverages disparities in affinity and intrinsic efficacy across divergent receptor targets or divergent functional states of the same target.
At the biochemical level, an agonist–antagonist typically operates through one of two distinct mechanisms: multitarget subtype-divergent modulation or context-dependent single-target partial agonism. In subtype-divergent modulation, the ligand possesses high affinity for two homologous yet functionally distinct receptor proteins. Upon binding, the ligand functions as a positive allosteric or orthosteric driver of the active state ($R^*$) in Receptor Subtype A (e.g., acting as an agonist), while stabilizing the inactive ground state ($R$) or competitively blocking access to Receptor Subtype B (acting as an antagonist). Consequently, the cellular output is a net integration of stimulated signaling via Subtype A and inhibited signaling via Subtype B.
In context-dependent single-target interactions, often exemplified by high-affinity partial agonists, the agonist–antagonist designation reflects the molecule’s behavior relative to ambient biological conditions. When endogenous neurotransmitter tone is low or zero, the molecule binds the receptor and induces sub-maximal intracellular signaling, behaving as an agonist. However, when high concentrations of a high-efficacy endogenous full agonist are present, the partial agonist displaces the full agonist from the orthosteric pocket due to its superior binding affinity. Because its intrinsic efficacy is lower than that of the displaced full agonist, the net biological response drops significantly, meaning the drug functionally acts as an antagonist against the native signaling baseline.
A crucial conceptual dimension of agonist–antagonist pharmacology is the ceiling effect (or plateau effect). Unlike full agonists, where biological response scales directly with receptor occupancy until absolute tissue system maximum is achieved, agonist–antagonists reach an intrinsic asymptote of pharmacological effect at sub-maximal biological levels. Increases in dosage beyond receptor saturation do not yield proportional increases in downstream physiological responses, such as respiratory suppression or analgesia. This molecular ceiling establishes an expansive therapeutic window and shields the biological system from lethal toxicities typical of uncontrolled full-agonist administration.
Finally, modern receptor pharmacology incorporates biased agonism (functional selectivity) into the agonist–antagonist framework. Receptors do not transition merely between single binary “on” and “off” states; rather, ligands can stabilize specific multidimensional conformations that preferentially activate one intracellular signaling cascade (e.g., G-protein-mediated cyclic adenosine monophosphate generation) while concurrently antagonizing or failing to recruit another (e.g., $\beta$-arrestin-mediated receptor internalization and inflammatory kinase signaling). Under this lens, an agonist–antagonist can exist at the level of a single receptor macromolecule acting on divergent intracellular effector pathways.
5. Historical Development
The genesis of agonist–antagonist pharmacology traces back to mid-twentieth-century efforts to disentangle the potent analgesic qualities of morphine from its catastrophic clinical liabilities: physical dependence, addiction liability, and fatal hypoventilation. In the 1940s and 1950s, researchers observed that the morphine derivative nalorphine (N-allylnormorphine) could precipitate acute withdrawal in morphine-dependent animals yet displayed independent, non-addictive pain-relieving capacity in human post-operative trials conducted by Lasagna and Beecher. This paradoxical revelation shattered the prevailing dogma that analgesia and addiction liability were inextricably linked pharmacological entities.
During the 1960s, medicinal chemist Sydney Archer and his colleagues synthesized pentazocine, the first commercially viable mixed agonist–antagonist analgesic. Pentazocine demonstrated that synthetic manipulation of the morphinan core could yield drugs capable of attenuating pain while antagonizing morphine-induced euphoria. In 1976, William R. Martin and his research team at the Addiction Research Center in Lexington, Kentucky, formalized the neurobiological basis for these observations. Through meticulous chronic spinal dog models, Martin demonstrated the existence of multiple opioid receptor subtypes—provisionally designated $\mu$ (mu), $kappa$ (kappa), and $\sigma$ (sigma)—proving that mixed agonist–antagonists derived their dual characteristics from disparate actions across distinct receptor entities.
The late 1960s and 1970s witnessed the development of buprenorphine by Reckitt & Colman (led by John W. Lewis). Synthesized from the thebaine alkaloid, buprenorphine exhibited an exceptionally high affinity but low intrinsic efficacy at the mu-opioid receptor, coupled with pure antagonism at the kappa-opioid receptor. Over the subsequent decades, the theoretical understanding transitioned from empirical observation of drug actions to molecular cloning of the opioid receptors ($u03bc, u03ba, u03b4$) in the early 1990s. The crystalline structure determinations of these receptors in active and inactive states during the 2010s finally resolved the atomic coordinates that permit agonist–antagonist compounds to stabilize subtype-specific conformations.
6. Theoretical Foundations
The theoretical underpinning of agonist–antagonist behavior relies upon classical and modern receptor theories. Clark’s pioneering Occupancy Theory presumed a linear relationship between the fraction of receptors occupied and the magnitude of the biological response. However, this model could not explain how two molecules occupying identical numbers of receptors could generate dramatically different biological magnitudes, nor could it rationalize how a drug could antagonize one response while initiating another.
To resolve these contradictions, Ariëns introduced the concept of intrinsic activity ($lpha$), defined as the proportional capacity of a drug-receptor complex to generate a biological stimulus. Under Ariëns’ formulation, full agonists possess $lpha = 1$, competitive antagonists possess $lpha = 0$, and partial agonists register between $0 < lpha < 1$. Soon after, Stephenson introduced the concept of efficacy ($e$), demonstrating that tissue response is a non-linear function of stimulus, and that drugs could elicit maximum responses without occupying all available receptors (introducing the concept of “spare receptors” or receptor reserve). Stephenson’s framework permitted mathematical modeling of how a partial agonist could act as a competitive antagonist against a ligand with higher efficacy.
Modern structural pharmacology contextualizes agonist–antagonist activity through the Ternary Complex Model and the Multi-State Conformational Model. Rather than existing in an equilibrium between static active ($R^*$) and inactive ($R$) states, G-protein-coupled receptors (GPCRs) sample an ensemble of intermediate energetic conformations. Agonist–antagonists shift this thermodynamic landscape unevenly:
- At one receptor subtype, the ligand stabilizes a state that coordinates G-protein heterotrimer binding, inducing GDP-GTP exchange.
- At another subtype, the physical volume or electrostatic profile of the ligand’s pharmacophore sterically prevents TM6 (transmembrane helix 6) outward displacement, locking the receptor in an inactive configuration that denies entry to downstream effectors.
Through these biophysical frameworks, modern pharmacology understands that agonist–antagonist behavior is not a biochemical contradiction, but the logical consequence of polypharmacology across a dynamic, multidimensional receptor proteome.
7. Key Components, Types & Dimensions
Agonist–antagonists can be classified into distinct operational categories based on their target receptor stoichiometry and molecular mechanisms of action:
- Subtype-Divergent Mixed Ligands: Compounds that bind orthosterically to two or more genetically distinct receptor subtypes within the same family, functioning as an agonist at one subtype and an antagonist at another.
- Example Profile: $kappa$-opioid receptor agonist combined with $\mu$-opioid receptor antagonist (e.g., nalbuphine, pentazocine).
- Context-Dependent Partial Agonists: Ligands acting at a single receptor subtype that possess intermediate intrinsic efficacy ($0 < lpha < 1$) and elevated receptor affinity. They produce agonism under states of low endogenous ligand presence and competitive antagonism under conditions of high native signaling flux.
- Example Profile: High-affinity, slow-dissociating partial $\mu$-opioid receptor agonist (e.g., buprenorphine).
- Functionally Selective (Biased) Agonist–Antagonists: Single-target ligands that selectively activate one intracellular signaling cascade (e.g., canonical G-protein coupling) while acting as functional antagonists against alternative downstream effectors (e.g., $\beta$-arrestin recruitment) at the exact same receptor macromolecule.
- Neurotransmitter Transporter Agonist–Antagonists: Neurochemical agents that facilitate substrate release at one monoaminergic transporter (e.g., dopamine transporter) while competitively blocking uptake or functioning as an antagonist at another (e.g., serotonin transporter).
8. Examples & Illustrative Cases
The clinical and laboratory utility of agonist–antagonists spans multiple drug classes, primarily centered on analgesia, neuropsychiatry, and substance use disorders.
- Buprenorphine: A potent partial $\mu$-opioid agonist and full $kappa$-opioid antagonist. It possesses an extremely low dissociation rate from the $\mu$-receptor, conferring long-lasting analgesia and suppression of illicit opioid cravings. Because it exerts competitive antagonism against exogenous full agonists like heroin or fentanyl, it prevents overdose toxicity while displaying an intrinsic ceiling on respiratory depression.
- Nalbuphine: A synthetic opioid that functions as a full $kappa$-opioid receptor agonist and a competitive $\mu$-opioid receptor antagonist. Clinically utilized in obstetrics and post-operative pain management, nalbuphine provides analgesia mediated by $kappa$-receptors without inducing significant $\mu$-mediated respiratory compromise or pruritus.
- Pentazocine: A benzomorphan derivative displaying agonist properties at $kappa$-opioid receptors and weak partial agonist/antagonist activity at $\mu$-opioid receptors. It represents an early model for non-scheduled or lower-schedule prescription analgesics, though its clinical deployment was partially curtailed by dysphoric psychological side effects linked to $kappa$ activation and off-target sigma site affinity.
- Varenicline: Outside the opioid domain, varenicline functions as a partial agonist at the $\alpha_4\beta_2$ nicotinic acetylcholine receptor subtype. In the absence of nicotine, it delivers modest dopamine release to diminish withdrawal symptoms; when the patient smokes cigarettes, varenicline blocks inhaled nicotine from binding the receptor, functionally antagonizing the euphoric burst associated with tobacco consumption.
Clinical Vignette: Precipitated Opioid Withdrawal
A 34-year-old individual with severe, active fentanyl dependence receives a therapeutic dose of sublingual buprenorphine too quickly after last fentanyl use. Because buprenorphine possesses a significantly higher binding affinity for the $\mu$-opioid receptor than fentanyl, it rapidly displaces fentanyl molecules from synaptic receptor pockets. However, because buprenorphine has low intrinsic efficacy compared to fentanyl, the net intracellular signaling drops precipitously within minutes. The patient instantly plunges into severe, acute “precipitated withdrawal,” characterized by autonomic hyperactivity, extreme diaphoresis, gastrointestinal cramping, and severe anxiety. This scenario demonstrates the potent antagonist dimension of an agonist–antagonist in real-world pharmacotherapy.
9. Measurement & Assessment
Characterizing the agonist–antagonist profile of a candidate molecule requires a battery of biophysical, functional, and computational screening paradigms:
- Radioligand Binding Assays: Competitive displacement assays using radiolabeled selective probes (e.g., $[^3\text{H}]\text{DAMGO}$ for $\mu$-receptors, $[^3\text{H}]\text{U-69,593}$ for $kappa$-receptors) allow investigators to calculate the inhibition constant ($K_i$) and verify binding affinity across homologous receptor targets.
- Functional $\text{[}^{35}\text{S]GTP}\gamma\text{S}$ Binding Assays: Because active GPCRs exchange GDP for GTP on the G$\alpha$ subunit, evaluating binding with non-hydrolyzable $[^{35}\text{S}]\text{GTP}\gamma\text{S}$ determines whether the ligand stimulates nucleotide exchange (agonism) or competitively suppresses agonist-stimulated exchange (antagonism).
- Bioluminescence Resonance Energy Transfer (BRET) Biosensors: Live-cell BRET platforms measure ligand-induced conformational changes, direct G-protein dissociation, and $\beta$-arrestin-1/2 recruitment in real time, determining signaling bias profiles.
- Schild Regression Analysis: By plotting pharmacological dose-ratios across escalating concentrations of the ligand against an established full agonist, the investigator calculates the $pA_2$ value, confirming whether antagonism is competitive, reversible, and orthosteric.
- Intracellular Second Messenger Quantitation: Measuring cyclic AMP (cAMP) accumulation or inhibition via enzyme fragment complementation, alongside intracellular calcium mobilization assays (e.g., Fluo-4 dyes), establishes functional concentration-response curves to define efficacy ($E_{\max}$) and potency ($EC_{50}$).
10. Applications & Practical Significance
Agonist–antagonists represent frontline therapeutic strategies across diverse branches of medical practice:
Addiction Medicine and Harm Reduction: The most prominent public health deployment of agonist–antagonist pharmacology occurs in the treatment of Opioid Use Disorder (OUD). Buprenorphine suppresses physical cravings and illicit drug self-administration while providing protection against fatal overdose. If a patient injects illicit street opioids concurrently, the antagonist properties of buprenorphine shield the brain from dangerous full-agonist activation. Formulations combining buprenorphine with naloxone (Suboxone) further weaponize this duality to prevent intravenous abuse: naloxone remains bio-inactive sublingually, but if injected parenterally, it antagonizes buprenorphine and triggers immediate withdrawal.
Anesthesiology and Perioperative Analgesia: Mixed agonist–antagonists like butorphanol and nalbuphine provide critical surgical analgesia without causing the intense respiratory depression characteristic of pure agonists like morphine, hydromorphone, or fentanyl. In pediatric, obstetric, and outpatient surgery contexts, nalbuphine is widely deployed to manage post-operative pain or to reverse pure-agonist-induced side effects (such as intolerable opioid-induced pruritus or urinary retention) without entirely abolishing systemic pain relief.
Psychiatric and Neuropsychiatric Interventions: Dysregulation of the endogenous dynorphin/$kappa$-opioid receptor axis is heavily implicated in treatment-resistant depression, dysphoria, and the negative affect associated with chronic stress. Agonist–antagonists functioning as functional $kappa$-receptor antagonists (such as buprenorphine) restore balance to mesolimbic reward circuits, attenuating depressive symptomatology and anhedonia in clinical trials.
11. Research & Empirical Evidence
Decades of rigorous preclinical and clinical trials have validated the mechanisms and real-world efficacy of agonist–antagonists. Seminal investigations led by Donald Jasinski at the Addiction Research Center established the safety profiles and unique clinical pharmacology of buprenorphine, validating that its partial agonist intrinsic efficacy prevented subjects from experiencing life-threatening respiratory collapse even at high escalations of dose.
In a landmark randomized clinical trial published in the New England Journal of Medicine, Fudala et al. (2003) demonstrated that office-based treatment with the buprenorphine/naloxone combination was exceptionally effective in reducing illicit opioid consumption and retaining participants in outpatient substance use treatment programs compared to placebo controls. This trial transformed global addiction medicine policies, shifting medication-assisted therapy out of heavily segregated methadone clinics into general primary care settings.
Cochrane systematic reviews (such as Mattick et al., 2014) synthesized dozens of randomized controlled trials comparing buprenorphine against full agonists like methadone. The analyses concluded that while methadone may retain patients in treatment slightly better at low dosages, buprenorphine exhibits an vastly superior safety profile regarding accidental fatal overdose, adverse cardiac events (such as QTc prolongation), and cognitive clouding.
In structural biology, the work of Brian Kobilka and colleagues (Manglik et al., 2012) resolved high-resolution crystal structures of opioid receptors bound to agonist and antagonist conformations. These structural discoveries visually validated how mixed ligands position distinct aromatic ring systems and bulky bridged morphinan structures within the receptor binding pocket to selectively toggle transmembrane domains, solidifying the atomic mechanics underlying agonist–antagonist pharmacology.
12. Cultural & Cross-Cultural Considerations
The societal and legal reception of agonist–antagonist medications varies dramatically across geopolitical landscapes. In Western nations like the United States, France, and Australia, buprenorphine is recognized as a cornerstone of harm-reduction strategy. In France, regulatory reforms in 1995 allowed all registered physicians to prescribe high-dose buprenorphine without special accreditation; this policy led to an immediate 79% reduction in national opioid overdose deaths over a four-year period—a public health achievement frequently cited as the “French Buprenorphine Revolution.”
Conversely, in many regions of Eastern Europe, Central Asia, and East Asia, profound sociocultural stigmas surrounding pharmacotherapy for addiction persist. Some jurisdictions operate under strict “zero-tolerance” frameworks that treat agonist–antagonists essentially like illicit opioids. In these contexts, legal statutes often fail to distinguish between full agonists (which induce escalating physical dependency and tolerance) and agonist–antagonists (which provide pharmacological stabilization and protective ceilings), blocking widespread access to life-saving maintenance medications.
Furthermore, international variations in controlled-substance scheduling create disparities in global availability. While the World Health Organization (WHO) has listed buprenorphine on its Model List of Essential Medicines since 2005, administrative hurdles, supply chain blockades, and restrictive national narcotics laws mean that over 80% of the world’s population lacks adequate access to essential agonist–antagonist analgesics and maintenance drugs, contributing to untreated pain and poorly managed substance use crises in low- and middle-income countries.
13. Criticisms, Debates & Limitations
Despite their exceptional clinical versatility, agonist–antagonists harbor distinct limitations and therapeutic challenges:
- The Analgesic Ceiling: The intrinsic ceiling effect that provides safety against respiratory depression also imposes an absolute limit on analgesia. In cases of severe polytrauma, extensive burn injuries, or terminal oncological pain, agonist–antagonists often prove inadequate, necessitating transfer to high-efficacy full agonists.
- Risk of Precipitated Withdrawal: Introducing an agonist–antagonist with high receptor affinity into a patient physically dependent on full agonists will displace the pure agonist and provoke rapid, excruciating withdrawal syndromes. Clinicians must carefully titrate induction periods (often requiring “micro-dosing” or Bernese induction protocols) to integrate the medication safely.
- Psychotomimetic and Dysphoric Effects: Compounds displaying substantial $kappa$-opioid receptor agonism (such as pentazocine or butorphanol) frequently provoke disturbing neuropsychiatric side effects, including depersonalization, vivid hallucinations, anhedonia, and dysphoria, severely restricting patient compliance.
- Resistance to Reversal: Buprenorphine binds to the $\mu$-receptor with such profound affinity and exhibits such a slow dissociation rate that in the rare event of severe pediatric toxicity or co-intoxication with central nervous system depressants, standard clinical doses of the pure antagonist naloxone may fail to displace it, requiring prolonged, continuous high-dose antagonist infusions.
14. Related Terms & Distinctions
Understanding the agonist–antagonist construct requires distinguishing it from adjacent pharmacological terms:
- Full Agonist: A compound that binds to a receptor and produces the maximal biological response achievable by that biological system ($lpha = 1.0$), without exhibiting antagonistic properties at any dosage.
- Pure (Neutral) Antagonist: A molecule that possesses high receptor affinity but zero intrinsic efficacy ($lpha = 0$). It produces no downstream biological response on its own; its sole effect is the passive blockade of endogenous or exogenous agonist binding.
- Inverse Agonist: An agent that binds to a constitutively active receptor (a receptor producing baseline signaling in the absence of any ligand) and actively reduces its baseline signaling rate below zero ($lpha < 0$). Unlike a neutral antagonist, an inverse agonist causes a directional negative response.
- Partial Agonist: A ligand that possesses affinity for a receptor but lower intrinsic efficacy than a full agonist ($0 < lpha < 1$). While every single-target agonist–antagonist exhibits partial agonist behavior, not all partial agonists are referred to as mixed agonist–antagonists unless contextual or multi-subtype antagonism is explicitly observed.
- Allosteric Modulator: A ligand that binds to a distinct, non-orthosteric binding pocket on the receptor protein to structurally alter receptor affinity or efficacy toward orthosteric ligands, without directly activating or competitively blocking the primary binding site.
15. Summary / Key Takeaways
The agonist–antagonist concept represents an indispensable paradigm in modern biomedical science. By combining receptor activation and inhibition within a single chemical entity, these compounds transcend traditional binary definitions of drug action. Whether achieving targeted multi-subtype balancing (such as $kappa$-agonism combined with $\mu$-antagonism) or high-affinity single-receptor partial agonism, agonist–antagonists deliver critical therapeutic safety advantages: robust clinical ceiling effects, mitigated overdose risks, and the ability to buffer physiological systems against external pharmacological disruptions. Mastering their molecular mechanisms is fundamental to modern therapeutics, spanning pain management, psychiatry, and the global public health struggle against substance use disorders.
In conclusion, agonist–antagonist ligands showcase the elegance of receptor pharmacology, where affinity and intrinsic efficacy combine to modulate physiological responses. By providing ceiling effects that prevent fatal overdose while delivering sustained therapeutic benefits, these molecules continue to reshape our approach to complex neurobiological pathways. As structural biology and computational drug discovery continue to map receptor signaling pathways, the design of next-generation agonist–antagonists promises safer, more targeted therapies for pain, mood disorders, and addiction.
References
- Archer, S., Albertson, N. F., Harris, L. S., Pierson, A. K., & Bird, J. G. (1964). Pentazocine. Strong analgesics and analgesic antagonists in the benzomorphan series. Journal of Medicinal Chemistry, 7(2), 123–127. https://doi.org/10.1021/jm00332a001
- Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., Ling, W., Malkerneker, U., McNicholas, L., Renner, J., Stine, S., & Tusel, D. (2003). Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine, 349(10), 949–958. https://doi.org/10.1056/NEJMoa022164
- Kenakin, T. (2019). A pharmacology primer: Techniques for more effective and strategic drug discovery (5th ed.). Academic Press. https://www.elsevier.com/books/a-pharmacology-primer/kenakin/978-0-12-813952-3
- Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Mathiesen, J. M., Sunahara, R. K., Pardo, L., Weis, W. I., Kobilka, B. K., & Granier, S. (2012). Crystal structure of the $\mu$-opioid receptor bound to a morphinan antagonist. Nature, 485(7398), 321–326. https://doi.org/10.1038/nature10954
- Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976). The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. Journal of Pharmacology and Experimental Therapeutics, 197(3), 517–532. https://jpet.aspetjournals.org/content/197/3/517
- Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews, 2014(2), CD002207. https://doi.org/10.1002/14651858.CD002207.pub4